Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
UNCY
Unicycive Therapeutics, Inc.
CAPPED RATING
Unicycive Therapeutics, Inc. (UNCY) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (A+); its weakest is Momentum (D).
Quantitative Factor Evaluation • Updated
Overall Rating
2.8
/ 5.0
C+
Value
B+
Factor Score
3.7
/ 5.0
Growth
A+
Factor Score
5.0
/ 5.0
Profitability
D
Factor Score
1.4
/ 5.0
Momentum
D
Factor Score
1.4
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
2.4
EV / EBITDA
-1.2
Rev Growth YoY
N/A
Gross Margin
0.0%
Price Return 3M
-36.3%
Price Return 12M
-30.9%
Catalyst Signal
0.00
Market Cap
$97.2M
TTM Revenue
N/A
Price / Sales
N/A
ROE
-101.1%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | B+ (3.7) | A+ (5.0) | D (1.4) | D (1.4) | C+ (2.6) | C+ (2.8) |
| 2026-11-08 | B+ (3.7) | A+ (5.0) | D (1.4) | D+ (1.7) | C+ (2.6) | B- (2.9) |
| 2026-11-01 | B+ (3.8) | A+ (5.0) | D+ (1.5) | D+ (1.8) | C+ (2.7) | B- (3.0) |
| 2026-10-25 | B+ (3.7) | A+ (5.0) | D (1.5) | D+ (1.8) | C+ (2.6) | B- (2.9) |
| 2026-10-18 | B+ (3.7) | A+ (5.0) | D (1.5) | D+ (1.6) | C+ (2.6) | B- (2.9) |
Page
1
of
3